Matrix Metalloproteinase-3 (MMP-3) Polymorphisms Are Associated with Prolonged ECG-Derived QTc Interval: A Cross-Sectional Study of the Australian Rural Population
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population and Design
2.2. Data Collection
2.3. Blood Collection and Biochemistry Assessment
2.4. Blood Pressure Measurements
2.5. 12-Lead Electrocardiogram (ECG)
2.6. DNA Genotyping
2.7. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Spadaccio, C.; Rainer, A.; Mozetic, P.; Trombetta, M.; Dion, R.A.; Barbato, R.; Nappi, F.; Chello, M. The role of extracellular matrix in age-related conduction disorders: A forgotten player? J. Geriatr. Cardiol. 2015, 12, 76–82. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.Y.; McTiernan, C.F.; Feldman, A.M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc. Res. 2000, 46, 214–224. [Google Scholar] [CrossRef] [Green Version]
- Ye, S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc. Res. 2006, 69, 636–645. [Google Scholar] [CrossRef] [PubMed]
- DeLeon-Pennell, K.Y.; Meschiari, C.A.; Jung, M.; Lindsey, M.L. Chapter two—Matrix metalloproteinases in myocardial infarction and heart failure. In Progress in Molecular Biology and Translational Science; Khalil, R.A., Ed.; Academic Press: Cambridge, MA, USA, 2017; Volume 147, pp. 75–100. [Google Scholar]
- Lombardi, F.; Belletti, S.; Battezzati, P.M.; Pacciolla, R.; Biondi, M.L. MMP-1 and MMP-3 polymorphism and arrhythmia recurrence after electrical cardioversion in patients with persistent atrial fibrillation. J. Cardiovasc. Med. 2011, 12, 37–42. [Google Scholar] [CrossRef]
- Mittal, R.; Patel, A.P.; Debs, L.H.; Nguyen, D.; Patel, K.; Grati, M.H.; Mittal, J.; Yan, D.; Chapagain, P.; Liu, X.Z. Intricate functions of matrix metalloproteinases in physiological and pathological conditions. J. Cell. Physiol. 2016, 231, 2599–2621. [Google Scholar] [CrossRef]
- Beton, O.; Arslan, S.; Acar, B.; Ozbilum, N.; Berkan, O. Association between MMP-3 and MMP-9 polymorphisms and coronary artery disease. Biomed. Rep. 2016, 5, 709–714. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Deguara, J.; Burnand, K.G.; Berg, J.; Green, P.; Lewis, C.M.; Chinien, G.; Waltham, M.; Taylor, P.; Stern, R.F.; Solomon, E.; et al. An increased frequency of the 5A allele in the promoter region of the MMP3 gene is associated with abdominal aortic aneurysms. Hum. Mol. Genet. 2007, 16, 3002–3007. [Google Scholar] [CrossRef]
- Kaplan, R.C.; Smith, N.L.; Zucker, S.; Heckbert, S.R.; Rice, K.; Psaty, B.M. Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis 2008, 201, 130–137. [Google Scholar] [CrossRef] [Green Version]
- Li, X.-P.; Wan, G.-Z.; Wang, G.-J.; Li, J.-F. MMP3 -1171 5A/6A Promoter Genotype Influences Serum MMP3 Levels and Is Associated with Deep Venous Thrombosis. Ann. Vasc. Surg. 2016, 34, 261–267. [Google Scholar] [CrossRef]
- Zachariah, J.P.; Colan, S.D.; Lang, P.; Triedman, J.K.; Alexander, M.E.; Walsh, E.P.; Berul, C.I.; Cecchin, F. Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ. Heart Fail. 2012, 5, 462–466. [Google Scholar] [CrossRef] [Green Version]
- Ye, S.; Eriksson, P.; Hamsten, A.; Kurkinen, M.; Humphries, S.E.; Henney, A.M. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 1996, 271, 13055–13060. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, C.; Odeberg, J.; Hamsten, A.; Eriksson, P. Allele-specific MMP-3 transcription under in vivo conditions. Biochem. Biophys. Res. Commun. 2006, 348, 1150–1156. [Google Scholar] [CrossRef] [PubMed]
- Humphries, S.; Bauters, C.; Meirhaeghe, A.; Luong, L.; Bertrand, M.; Amouyel, P. The 5A6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene as a risk factor for restenosis. Eur. Heart J. 2002, 23, 721–725. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pawlik, A.; Plucinska, M.; Kopec, M.; Głabowski, D.; Czerewaty, M.; Safranow, K. MMP1 and MMP3 gene polymorphisms in patients with acute coronary syndromes. IUBMB Life 2017, 69, 850–855. [Google Scholar] [CrossRef] [Green Version]
- Bednar, M.M.; Harrigan, E.P.; Anziano, R.J.; Camm, A.J.; Ruskin, J.N. The QT interval. Prog. Cardiovasc. Dis. 2001, 43, 1–45. [Google Scholar]
- Burns, C.; Ingles, J.; Davis, A.M.; Connell, V.; Gray, B.; Hunt, L.; McGaughran, J.; Semsarian, C. Clinical and genetic features of Australian families with long QT syndrome: A registry-based study. J. Arrhythm. 2016, 32, 456–461. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rautaharju, P.M.; Surawicz, B.; Gettes, L.S.; Bailey, J.J.; Childers, R.; Deal, B.J.; Gorgels, A.; Hancock, E.W.; Josephson, M.; Kligfield, P.; et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part IV: The ST segment, T and U waves, and the QT interval: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J. Am. Coll. Cardiol. 2009, 53, 982–991. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mangoni, A.A.; Kinirons, M.T.; Swift, C.G.; Jackson, S.H. Impact of age on QT interval and QT dispersion in healthy subjects: A regression analysis. Age Ageing 2003, 32, 326–331. [Google Scholar] [CrossRef] [Green Version]
- Rabkin, S.W.; Cheng, X.-B.J.; Thompson, D.J. Detailed analysis of the impact of age on the QT interval. J. Geriatr. Cardiol. 2016, 13, 740–748. [Google Scholar] [CrossRef]
- Reardon, M.; Malik, M. QT interval change with age in an overtly healthy older population. Clin. Cardiol. 1996, 19, 949–952. [Google Scholar] [CrossRef]
- Zhang, Y.; Post, W.S.; Blasco-Colmenares, E.; Dalal, D.; Tomaselli, G.F.; Guallar, E. Electrocardiographic QT interval and mortality: A meta-analysis. Epidemiology 2011, 22, 660. [Google Scholar] [CrossRef] [Green Version]
- Olejarz, W.; Łacheta, D.; Kubiak-Tomaszewska, G. Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability. Int. J. Mol. Sci. 2020, 21, 3946. [Google Scholar] [CrossRef] [PubMed]
- Meschiari, C.A.; Ero, O.K.; Pan, H.; Finkel, T.; Lindsey, M.L. The impact of aging on cardiac extracellular matrix. Geroscience 2017, 39, 7–18. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, T.P.; Qu, Z.; Weiss, J.N. Cardiac fibrosis and arrhythmogenesis: The road to repair is paved with perils. J. Mol. Cell. Cardiol. 2014, 70, 83–91. [Google Scholar] [CrossRef] [Green Version]
- Nielsen, M.S.; Axelsen, L.N.; Sorgen, P.L.; Verma, V.; Delmar, M.; Holstein-Rathlou, N.-H. Gap junctions. Compr. Physiol. 2012, 2, 1981–2035. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Bock, M.; Wang, N.; Decrock, E.; Bultynck, G.; Leybaert, L. Intracellular cleavage of the Cx43 C-terminal domain by matrix-metalloproteases: A novel contributor to inflammation? Mediat. Inflamm. 2015, 2015, 257471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peng, H.-J.; Dai, D.-Z.; Ji, H.; Dai, Y. The separate roles of endothelin receptors participate in remodeling of matrix metalloproteinase and connexin 43 of cardiac fibroblasts in maladaptive response to isoproterenol. Eur. J. Pharmacol. 2010, 634, 101–106. [Google Scholar] [CrossRef] [PubMed]
- Jansen, J.A.; van Veen, T.A.; de Jong, S.; van der Nagel, R.; van Stuijvenberg, L.; Driessen, H.; Labzowski, R.; Oefner, C.M.; Bosch, A.A.; Nguyen, T.Q. Reduced Cx43 expression triggers increased fibrosis due to enhanced fibroblast activity. Circ. Arrhythm. Electrophysiol. 2012, 5, 380–390. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Olsen, V.; Rohde, L.E.; Beck-da-Silva, L.; Santos, K.G.; Biolo, A.; Clausell, N.; Andrades, M. QRS widening rates and genetic polymorphisms of matrix metalloproteinases in a cohort of patients with chronic heart failure. Can. J. Cardiol. 2014, 30, 345–351. [Google Scholar] [CrossRef]
- Spinale, F.G.; Coker, M.L.; Heung, L.J.; Bond, B.R.; Gunasinghe, H.R.; Etoh, T.; Goldberg, A.T.; Zellner, J.L.; Crumbley, A.J. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102, 1944–1949. [Google Scholar] [CrossRef] [Green Version]
- Malik, M.; Färbom, P.; Batchvarov, V.; Hnatkova, K.; Camm, A. Relation between QT and RR intervals is highly individual among healthy subjects: Implications for heart rate correction of the QT interval. Heart 2002, 87, 220–228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Batchvarov, V.N.; Ghuran, A.; Smetana, P.; Hnatkova, K.; Harries, M.; Dilaveris, P.; Camm, A.J.; Malik, M. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am. J. Physiol. Heart Circ. Physiol. 2002, 282, H2356–H2363. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Desai, M.; Li, L.; Desta, Z.; Malik, M.; Flockhart, D. Variability of heart rate correction methods for the QT interval. Br. J. Clin. Pharmacol. 2003, 55, 511–517. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goldenberg, I.; Moss, A.J.; Zareba, W. QT interval: How to measure it and what is “normal”. J. Cardiovasc. Electrophysiol. 2006, 17, 333–336. [Google Scholar] [CrossRef]
Factor | Mean ± SD | N (%) |
---|---|---|
N | 295 | |
Age (years) | 64.88 ± 10.17 | - |
Sex | ||
Female (%) | 169 (57.3) | |
Male (%) | 126 (42.7) | |
BMI (kg/m2) | 28.42 ± 4.93 | |
Diabetes mellitus | ||
Prediabetes (%) | 1 (0.3) | |
Type I (%) | 5 (1.7) | |
Type II (%) | 89 (31.2) | |
Cardiovascular disease (%) | 65 (22.0) | |
Hypertension (%) | 162 (54.9) | |
Smoking (%) | 6 (2.0) | |
Alcohol (%) | 24 (8.1) | |
SBP (mmHg) | 130.19 ± 17.42 | |
DBP (mmHg) | 76.61 ± 9.81 | |
Glucose (mM) | 6.04 ± 2.57 | |
HbA1c (%) | 6.11 ± 1.13 | |
TC (mM) | 5.00 ± 1.17 | |
triglyceride (mM) | 1.41 ± 0.80 | |
HDLc (mM) | 1.37 ± 0.38 | |
LDLc (mM) | 3.00 ± 1.04 | |
TC/HDL | 3.82 ± 1.09 | |
PQi (ms) | 174.58 ± 28.24 | |
QRSd (ms) | 101.54 ± 17.65 | |
QTc (ms) | 429.42 ± 23.04 | |
QTd (ms) | 62.77 ± 32.43 |
5A/5A (n = 85) | 5A/6A (n = 141) | 6A/6A (n = 69) | |||||
---|---|---|---|---|---|---|---|
Coefficient * | 95% CI | Coefficient * | 95% CI | ||||
SBP | Reference ^ | 0.21 | (−4.51, 4.94) | 0.930 | −0.46 | (−6.04, 5.11) | 0.871 |
DBP | Reference ^ | −0.14 | (−2.79, 2.51) | 0.918 | 1.79 | (−1.34, 4.91) | 0.262 |
PQ | Reference ^ | −3.82 | (−11.52, 3.86) | 0.328 | −8.10 | (−17.18, 0.99) | 0.081 |
QRS | Reference ^ | 2.51 | (−2.26, 7.28) | 0.301 | 3.53 | (−2.11, 9.16) | 0.219 |
QTc | Reference ^ | 9.83 | (3.71, 15.94) | 0.002 | 11.31 | (4.09, 18.53) | 0.002 |
QTd | Reference ^ | −0.68 | (−10.01, 8.66) | 0.887 | 0.94 | (−10.03, 11.91) | 0.866 |
5A/5A | 5A/6A | 6A/6A | |||||
---|---|---|---|---|---|---|---|
Coefficient * | 95%CI | Coefficient * | 95%CI | ||||
PQ | Reference ^ | −3.74 | (−11.14, 3.65) | 0.320 | −8.33 | (−17.14, 0.47) | 0.063 |
QRS | Reference ^ | 2.54 | (−2.01, 7.09) | 0.272 | 3.033 | (−2.37, 8.44) | 0.270 |
QTc | Reference ^ | 9.50 | (3.48, 15.52) | 0.002 | 12.19 | (5.04, 19.34) | 0.001 |
QTd | Reference ^ | −0.50 | (−9.87, 8.87) | 0.916 | 1.64 | (−9.45, 12.72) | 0.771 |
5A/5A | 5A/6A | 6A/6A | |||||
---|---|---|---|---|---|---|---|
OR * | 95%CI | OR * | 95%CI | ||||
Diabetes mellitus | 1.00 | 1.00 | (0.55, 1.52) | 0.999 | 1.23 | (0.61, 2.48) | 0.566 |
CVD | 1.00 | 1.54 | (0.76, 3.13) | 0.234 | 1.04 | (0.44, 2.45) | 0.934 |
Hypertension | 1.00 | 0.74 | (0.41, 1.35) | 0.331 | 1.03 | (0.50, 2.12) | 0.928 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lu, Y.; Ussher, N.; Zhou, Y.; Jelinek, H.; Hambly, B.; Li, A.; McLachlan, C.S. Matrix Metalloproteinase-3 (MMP-3) Polymorphisms Are Associated with Prolonged ECG-Derived QTc Interval: A Cross-Sectional Study of the Australian Rural Population. J. Pers. Med. 2021, 11, 705. https://doi.org/10.3390/jpm11080705
Lu Y, Ussher N, Zhou Y, Jelinek H, Hambly B, Li A, McLachlan CS. Matrix Metalloproteinase-3 (MMP-3) Polymorphisms Are Associated with Prolonged ECG-Derived QTc Interval: A Cross-Sectional Study of the Australian Rural Population. Journal of Personalized Medicine. 2021; 11(8):705. https://doi.org/10.3390/jpm11080705
Chicago/Turabian StyleLu, Yaxin, Nathan Ussher, Yuling Zhou, Herbert Jelinek, Brett Hambly, Amy Li, and Craig S. McLachlan. 2021. "Matrix Metalloproteinase-3 (MMP-3) Polymorphisms Are Associated with Prolonged ECG-Derived QTc Interval: A Cross-Sectional Study of the Australian Rural Population" Journal of Personalized Medicine 11, no. 8: 705. https://doi.org/10.3390/jpm11080705